Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

22.00 +0.39 (+1.80%)
Streaming Delayed Price Updated: 3:44 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Combines Strong Fundamentals with Bullish Technicals for Growth Potential ↗
ACADIA Pharmaceuticals (ACAD) shows strong growth fundamentals with rising revenue, EPS, and solid margins, plus a bullish technical breakout, making it a promising stock pick. 
Via Chartmill
News headline image
Acadia (ACAD) Q2 Revenue Rises 9% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Q2 2025 Earnings: Revenue Growth Meets Expectations, EPS Beats Estimates ↗
Acadia Pharmaceuticals reports Q2 2025 earnings with $264.6M revenue (+9% YoY), EPS beats at $0.16. NUPLAZID & DAYBUE sales grow, reaffirms full-year guidance. Stock up 12.5% in past month. 
Via Chartmill
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
The Analyst Verdict: ACADIA Pharmaceuticals In The Eyes Of 11 Experts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Demystifying ACADIA Pharmaceuticals: Insights From 5 Analyst Reviews ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A High-Growth Biotech Stock with Fair Valuation ↗
ACADIA Pharmaceuticals (ACAD) offers strong growth, solid profitability, and fair valuation, making it a top pick for investors seeking affordable growth in biotech. 
Via Chartmill
News headline image
What Analysts Are Saying About ACADIA Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Growth Stock with Technical Breakout Potential ↗
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) shows strong growth fundamentals and a bullish technical setup, making it a noteworthy stock for growth investors. 
Via Chartmill
News headline image
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Growth Stock at a Reasonable Valuation ↗
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it a compelling candidate for growth... 
Via Chartmill
News headline image
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Growth Stock with Technical Breakout Potential ↗
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) shows strong growth fundamentals and a bullish technical setup, making it a stock to watch for potential breakout opportunities. 
Via Chartmill
News headline image
13 Analysts Assess ACADIA Pharmaceuticals: What You Need To Know ↗
 
Via Benzinga
News headline image
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Affordable Growth Stock ↗
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it an interesting candidate for growth... 
Via Chartmill
News headline image
JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory ↗
Acadia wins Nuplazid patent case, extending protection to 2038, as JP Morgan boosts price target ahead of key appeal on the ‘740 COM patent. 
Via Benzinga
Topics Intellectual Property
News headline image
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Growth Stock at a Reasonable Valuation ↗
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it an interesting stock for growth investors. 
Via Chartmill
News headline image
These Analysts Boost Their Forecasts On Acadia Pharmaceuticals ↗
 
Via Benzinga
News headline image
Forecasting The Future: 8 Analyst Projections For ACADIA Pharmaceuticals ↗
 
Via Benzinga
News headline image
Netflix To $1,220? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
Acadia Pharmaceuticals (ACAD) Stock Explodes 26% After Patent Court Victory ↗
ACADIA Pharmaceuticals stock jumped 26.4% Friday afternoon. Shares gained following a favorable court ruling. 
Via Benzinga
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Top stock movements in today's session. ↗
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Evolv Technologies, Quantum Computing, ACADIA Pharmaceuticals And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
The market is filled with gapping stocks in Friday's session. ↗
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
News headline image
NASDAQ:ACAD, an undervalued stock with good fundamentals. ↗
ACADIA PHARMACEUTICALS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:ACAD showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
News headline image
While growth is established for NASDAQ:ACAD, the stock's valuation remains reasonable. ↗
ACADIA PHARMACEUTICALS INC was identified as an affordable growth stock. NASDAQ:ACAD is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably. 
Via Chartmill
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.